

AION THERAPEUTIC INC.
700 W Georgia St Suite 2200
Vancouver, BC
V7Y 1K8 CA

2024 SUPPLY CHAIN ACT ANNUAL REPORT

This inaugural Annual Report (the “**Report**”) is produced in accordance with section 11 of the *Fighting Against Forced Labour and Child Labour in Supply Chains Act* (the “**Supply Chains Act**” or the “**Act**”) and is filed for Aion Therapeutic Inc. (“**Aion**”) covering the twelve-month financial year ended **April 30, 2024** (the “**Reporting Period**”).

1. Our Structure, Operations and Supply Chains

Aion is a reporting issuer in the Provinces of British Columbia and is listed on the CSE under the symbol “AION”.

As of May 30, 2024, Aion employs eight (8) people, of which zero (0) are located in Canada and eight (8) are located in the United States.

Aion is a forward-thinking business (CSE: AION) within the health and wellness sector with a diverse portfolio of intellectual property. With a commitment to innovation and transformative solutions, the Company is poised to drive positive change to redefine the boundaries of health and wellness.

On December 15, 2023, Aion acquired Toppen Health Inc. (“Toppen”), a US-based innovative health and wellness company dedicated to delivering state-of-the-art water filtration solutions.

Through Toppen, Aion operates a 7,500 sq-ft manufacturing facility based in Sanford, Florida, for the purposes of producing water filtration parts and systems.

Through Toppen, Aion markets and sells its products through various channels, including retail, distribution, and industrial channels. Toppen relies on a network of suppliers for the filters and components used in its filtration systems. Its supply chain involves purchasing a diverse range of goods and services, predominantly sourced from North American suppliers.

2. The Steps We Have Taken in the Reporting Period to Prevent and Reduce the Risk of Forced Labour and Child Labour

During the Reporting Period, we have not performed an assessment of the countries or origin of the raw material used in our manufacturing process and contained in the products we sell, distribute or import and the type of suppliers making up our supply chains.

3. Policies, Due Diligence and Controls

At the moment, we do not have policies regarding forced labour, child labour or human rights in general. We have not developed due diligence processes or controls in regard to these topics.

Nonetheless, we aim to develop in the future policies tackling these issues to ensure that instances of forced labour or child labour in our operations and supply chains may be uncovered and addressed.

4. Risk Assessment Methodology and Results of Assessment

During the Reporting Period, we did not make any assessment of the potential risk related to forced labour and child labour in our operations and supply chains. In the future, we plan to roll-out a compliance program, which may include a questionnaire designed to specifically address the issue of forced labour and child labour which we initially plan to send to our Tier 1 (direct) suppliers.

5. Risks of Forced Labour and Child Labour in our Operations and Supply Chains

To the best of our knowledge, during the Reporting Period we have not identified risks of forced labour and child labour in our operations and supply chains. Our risk assessment process is currently non-existent. We have a goal of possibly setting up a compliance program to address this issue during our current financial year.

6. Remedial Action Taken during the Reporting Period

No, we have not taken any remediation measures during the Reporting Period.

7. Our remediation processes

Since we have no compliance program addressing specifically the issue of forced labour and child labour in our operations and supply chains, we have currently no remediation process in place to deal with this issue.

8. Remediation actions for the loss of income to the most vulnerable families that results from any measure taken to eliminate forced labour and child labour from our operations and supply chains

No, we have not taken any remediation measures.

9. Our training

We have no director, officer or staff training in place at the moment dealing with forced labour and child labour in our operations and supply chains.

10. Assessing our effectiveness

No assessment of our effectiveness to prevent and reduce the occurrence of forced labour and child labour in our operations and supply chains was conducted during the Reporting Period, and until we put in place a compliance program to address this issue we are not contemplating doing so.

11. Our consultation and governance process

In preparing this Report, we consulted our external legal counsel. We have no governance process related to preventing and reducing the occurrence of forced labour and child labour in our operations and supply chains, except for having this report approved by the board of directors of Aion.

12. Approval

This Report was approved by the board of directors of Aion pursuant to Subsection 11(4)(b)(ii) of the Act on May 30, 2024.

13. Attestation

In accordance with the requirements of the Act, and in particular section 11 thereof, I attest that I have reviewed the information contained in the Report for the entity or entities listed above. Based on my knowledge and having exercised reasonable diligence, I attest that the information in the report is true, accurate and complete in all material respects for the purposes of the Act, for the reporting year listed above.

Dated this 30th day of May, 2024

AION THERAPEUTIC INC.

Per: (signed) "Graham Simmonds"

Name: Graham Simmonds

Title: Executive Vice Chair & CEO

I have the power to bind Aion Therapeutics Inc.